Skip to main content
Caplight Logo









Ablaze Pharmaceuticals

Ablaze Pharmaceuticals

Private
ShanghaiHealthcare & Life Scienceshttps://ablazepharma.com

Last Round

Series A

Nov 29, 2021

Total Funding Raised

$75M

Company Overview

Ablaze Pharmaceuticals is a biopharmaceutical company specializing in the development of Targeted Radiotherapy (TRT) treatments for cancer patients in the Chinese market.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

targeted radiopharmaceutical therapiesTRTradiopharmaradioligand therapyGPC3 targeted therapyliver cancer treatmentclinical-stage biopharmadrug in-licensingoncologyactinium-225 therapylutetium-177 therapyalpha emitter therapynuclear medicinesolid tumor therapyChina healthcare market

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ablaze Pharmaceuticals Comparables

Compare Ablaze Pharmaceuticals with similar companies based on industry and business-model similarity.

Ablaze Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AlphaGen Therapeutics
89%
C-Ray Therapeutics
88%
Yantai Lannacheng Biotechnology Co., Ltd.
84%

Ablaze Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 29, 2021

Key People

Founding team and executive leadership

Alan Xu

Co-Founder And Chief Operating Officer

Founding Team

Ablaze Pharmaceuticals Investors

Notable investors and investment history

Ablaze Pharmaceuticals investors
InvestorRounds
Nan Fung Life SciencesSeries A
Advantech CapitalSeries A
Nan Fung GroupSeries A
venBioSeries A
VenrockSeries A
Samsara BioCapitalSeries A
Vivo CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 29, 2021

    $75M round led by Vivo Capital and Advantech Capital.

Ablaze Pharmaceuticals Filings

Explore SEC and related filing metadata, where available.

Ablaze Pharmaceuticals filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Ablaze Pharmaceuticals's valuation, stock price, and market status.

Is Aboz Pharmaceuticals a public or private company?

Aboz Pharmaceuticals is a private company.

What is the current stock price of Aboz Pharmaceuticals?

Aboz Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.

How much is Aboz Pharmaceuticals worth (valuation)?

Valuation information for Aboz Pharmaceuticals is not publicly available.

Can I buy Aboz Pharmaceuticals stock?

Aboz Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Aboz Pharmaceuticals's last funding round?

Aboz Pharmaceuticals's most recent funding round was Series A on November 29, 2021.

Who are the main investors in Aboz Pharmaceuticals?

Key investors in Aboz Pharmaceuticals include Advantech Capital, Vivo Capital.

Will Aboz Pharmaceuticals IPO soon?

No public IPO plans have been announced for Aboz Pharmaceuticals.

How can I track Aboz Pharmaceuticals secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Aboz Pharmaceuticals's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai
Employee Range3
Year Founded2021
Last FundingNov 29, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?